Usana Health Sciences, Inc. logo

Usana Health Sciences, Inc. (USNA)

Market Closed
3 Jun, 20:00
NYSE NYSE
$
17. 46
-0.59
-3.27%
$
347.84M Market Cap
13.24 P/E Ratio
- Div Yield
89,162 Volume
2.72 Eps
$ 18.05
Previous Close
Add Transaction
Day Range
17.36 18.03
Year Range
16.6 38.32
Want to track USNA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
USNA or ZTS: Which Is the Better Value Stock Right Now?

USNA or ZTS: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?

Zacks | 10 months ago
USANA Health Sciences: Hiya's Potential Is Showing

USANA Health Sciences: Hiya's Potential Is Showing

USANA Health Sciences is resurfacing as an idea after a strong Q2 report. The direct selling business has continued to struggle with a decline in sales and active customers. A segment turnaround remains uncertain. The previous Hiya acquisition's potential is clearly showing. Operational expansion underlines massive long-term potential for USANA.

Seekingalpha | 10 months ago
USANA Health Sciences, Inc. (USNA) Q2 2025 Earnings Call Transcript

USANA Health Sciences, Inc. (USNA) Q2 2025 Earnings Call Transcript

USANA Health Sciences, Inc. (NYSE:USNA ) Q2 2025 Earnings Conference Call July 23, 2025 11:00 AM ET Company Participants Andrew Masuda - Director of Investor Relations Brent L. Neidig - Chief Commercial Officer G.

Seekingalpha | 10 months ago
USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates

USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates

USANA Health Sciences (USNA) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.54 per share a year ago.

Zacks | 10 months ago
USANA Health Sciences: Premium Formulation, Discounted Valuation

USANA Health Sciences: Premium Formulation, Discounted Valuation

USANA Health Sciences' pivot from MLM to omnichannel, highlighted by the Hiya Health acquisition, marks a strategic inflection point for renewed growth and relevance. The company's scientific credibility, strong balance sheet, and global reach position it well, despite recent revenue declines and heavy China exposure. Valuation is attractive at 12× forward earnings and 5× EBITDA, with catalysts including Hiya's growth, margin expansion, and potential buybacks.

Seekingalpha | 11 months ago
USNA vs. STVN: Which Stock Is the Better Value Option?

USNA vs. STVN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?

Zacks | 11 months ago
USANA Health (USNA) Upgraded to Buy: Here's What You Should Know

USANA Health (USNA) Upgraded to Buy: Here's What You Should Know

USANA Health (USNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 11 months ago
Is USANA Health Sciences (USNA) Stock Undervalued Right Now?

Is USANA Health Sciences (USNA) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 11 months ago
USANA Health Sciences, Inc. (USNA) Q1 2025 Earnings Call Transcript

USANA Health Sciences, Inc. (USNA) Q1 2025 Earnings Call Transcript

USANA Health Sciences, Inc. (NYSE:USNA ) Q1 2025 Earnings Conference Call April 23, 2025 11:00 AM ET Company Participants Andrew Masuda - Director, Investor Relations Jim Brown - President and Chief Executive Officer Brent Neidig - Chief Commercial Officer Doug Hekking - Chief Financial Officer Walter Noot - Chief Operating Officer Conference Call Participants Anthony Lebiedzinski - Sidoti & Company Ivan Feinseth - Tigress Financial Partners Operator Greetings. Welcome to the USANA Health Sciences First Quarter Conference Call.

Seekingalpha | 1 year ago
USANA Health Sciences (USNA) Q1 Earnings and Revenues Surpass Estimates

USANA Health Sciences (USNA) Q1 Earnings and Revenues Surpass Estimates

USANA Health Sciences (USNA) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.70 per share. This compares to earnings of $0.86 per share a year ago.

Zacks | 1 year ago
USANA Health Sciences, Inc. (USNA) Q4 2024 Earnings Conference Call Transcript

USANA Health Sciences, Inc. (USNA) Q4 2024 Earnings Conference Call Transcript

USANA Health Sciences, Inc. (NYSE:USNA ) Q4 2024 Earnings Conference Call February 26, 2025 11:00 AM ET Company Participants Andrew Masuda - IR Jim Brown - President and CEO Brent Neidig - Chief Commercial Officer Doug Hekking - CFO Walter Noot - COO Conference Call Participants Anthony Lebiedzinski - Sidoti Christina Xue - D.A. Davidson Ivan Feinseth - Tigress Financial Partners Doug Lane - Water Tower Research Operator Greetings, and welcome to the USANA Health Sciences' Fourth Quarter Conference Call.

Seekingalpha | 1 year ago
USANA Health Sciences (USNA) Surpasses Q4 Earnings and Revenue Estimates

USANA Health Sciences (USNA) Surpasses Q4 Earnings and Revenue Estimates

USANA Health Sciences (USNA) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.87 per share a year ago.

Zacks | 1 year ago
Loading...
Load More